FY2029 Earnings Forecast for SAGE Issued By Wedbush

Sage Therapeutics, Inc. (NASDAQ:SAGE) – Equities research analysts at Wedbush issued their FY2029 earnings per share estimates for Sage Therapeutics in a research note issued to investors on Thursday, January 23rd. Wedbush analyst L. Chico anticipates that the biopharmaceutical company will earn $0.35 per share for the year. Wedbush currently has a “Neutral” rating and a $8.00 target price on the stock. The consensus estimate for Sage Therapeutics’ current full-year earnings is ($6.47) per share.

Sage Therapeutics (NASDAQ:SAGE) last released its earnings results on Tuesday, October 29th. The biopharmaceutical company reported ($1.53) earnings per share for the quarter, missing the consensus estimate of ($1.52) by ($0.01). The business had revenue of $11.87 million for the quarter, compared to analysts’ expectations of $10.80 million. Sage Therapeutics had a negative net margin of 317.29% and a negative return on equity of 50.29%. The company’s revenue was up 337.1% compared to the same quarter last year. During the same period last year, the firm earned ($2.81) EPS.

SAGE has been the topic of a number of other reports. Bank of America dropped their price target on shares of Sage Therapeutics from $11.00 to $6.00 and set an “underperform” rating on the stock in a research note on Wednesday, October 9th. Piper Sandler dropped their price target on shares of Sage Therapeutics from $26.00 to $9.00 and set an “overweight” rating on the stock in a research report on Thursday, January 2nd. Raymond James restated a “market perform” rating on shares of Sage Therapeutics in a research note on Thursday, October 10th. Royal Bank of Canada upgraded shares of Sage Therapeutics from an “underperform” rating to a “sector perform” rating and set a $4.00 price objective on the stock in a report on Thursday, November 21st. Finally, StockNews.com lowered Sage Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, October 31st. Three equities research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $10.53.

Sage Therapeutics Stock Up 0.1 %

Shares of SAGE opened at $7.02 on Friday. The company’s 50 day moving average price is $5.76 and its 200 day moving average price is $7.39. Sage Therapeutics has a 52 week low of $4.62 and a 52 week high of $27.67.

Institutional Trading of Sage Therapeutics

Several large investors have recently added to or reduced their stakes in SAGE. State Street Corp boosted its holdings in shares of Sage Therapeutics by 18.2% in the 3rd quarter. State Street Corp now owns 2,926,239 shares of the biopharmaceutical company’s stock worth $21,127,000 after acquiring an additional 451,377 shares in the last quarter. RTW Investments LP boosted its stake in Sage Therapeutics by 2.0% in the third quarter. RTW Investments LP now owns 5,591,700 shares of the biopharmaceutical company’s stock worth $40,372,000 after purchasing an additional 111,123 shares in the last quarter. Charles Schwab Investment Management Inc. increased its stake in shares of Sage Therapeutics by 10.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 452,193 shares of the biopharmaceutical company’s stock valued at $3,265,000 after buying an additional 43,617 shares in the last quarter. Renaissance Technologies LLC raised its stake in shares of Sage Therapeutics by 1,476.6% in the second quarter. Renaissance Technologies LLC now owns 553,396 shares of the biopharmaceutical company’s stock worth $6,010,000 after acquiring an additional 518,296 shares during the last quarter. Finally, AQR Capital Management LLC acquired a new position in shares of Sage Therapeutics during the second quarter worth approximately $1,008,000. 99.22% of the stock is owned by institutional investors.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.